Form 8-K - Current report:
SEC Accession No. 0001213900-24-072570
Filing Date
2024-08-26
Accepted
2024-08-26 15:32:49
Documents
14
Period of Report
2024-08-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021239701-8k_elevailab.htm   iXBRL 8-K 27312
2 PRESS RELEASE OF ELEVAI LABS, INC. DATED AS OF AUGUST 26, 2024. ea021239701ex99-1_elevailab.htm EX-99.1 11782
  Complete submission text file 0001213900-24-072570.txt   220048

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE elab-20240826.xsd EX-101.SCH 3030
4 XBRL LABEL FILE elab-20240826_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE elab-20240826_pre.xml EX-101.PRE 22369
16 EXTRACTED XBRL INSTANCE DOCUMENT ea021239701-8k_elevailab_htm.xml XML 3803
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241240821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)